RE:RE:RE:That's it I'm outYes Fairweather, you are probably right: there might be some profit-taking going on, based on the large gains over the past few months. However, it could be argued that the run-up was justified. CAS turned in a profit of 52 cents per share in Q3 2015 and its Q4 profits should be even higher (weaker CND vs. USD). 2016 profits could be anywhere between $ 1.5 and $ 2.0 per share, if the US economy holds. This would easily justify a share price of $ 13/share. As to sensitivity to an economic slow-down, the tissue sector is relatively insensitive, but the packaging busines (the great majority of CAS' sales) is quite sensitive to GDP. Therefore, if the US economy slows down, that part of the business will suffer.
The fact remainst that CAS has lost about 30% of its value in a week and seems to have become a radiactive commodity: nobody wants to be near it. I am holding on, but, so far, I have been foolish to do so.
In any case, Best of luck to all investors.